Nuclear fusion technology company SHINE Technologies LLC announced Friday that the company had submitted a drug master file (DMF) with the U.S. Food and Drug Administration (FDA) for a radioisotope used in cancer treatment.

The cancer-killing radioisotope, lutetium-177 (Lu-177), is paired with a cancer-seeking molecule used in cancer therapy to help target and attack cancer cells, according to a press release.

The FDA submission allows SHINE’s customers for Lu-177 – which are mainly pharmaceutical companies – to reference the file in order to use the radioisotope in clinical trials, said Todd Asmuth, president and chief strategy officer of Janesville-based SHINE Technologies.

Click here to read the full article.